Stryker launches state-of-the-art Neurovascular R&D lab with advanced technology to accelerate stroke care innovation

Posted on by admin

Stryker, one of the world’s leading medical technology companies, recently opened its Neurovascular (NV) lab, a state-of-the-art lab designed to accelerate stroke-related innovation in Asia Pacific. Located within the Stryker Global Technology Center (SGTC) at International Park, Gurgaon, India, the Keystone Suite will enable collaboration between customers, product development engineers, cross-functional teams, and other key […]

Read More

Merrimack provides Ipsen report that Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

Posted on by admin

Cambridge, MA, November 9, 2022 /Business Wire/ – Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a […]

Read More

Utah Life Sciences Companies participate in Utah Trade Delegation to Medica 2022

Posted on by admin

Exhibiting their innovative products and services to over 80,000 visitors, 11 life science companies represented Utah at the MEDICA trade show in Düsseldorf, Germany. Looking across the global landscape of innovative healthcare products, Charlotte Serage, WTC Utah’s manager of trade shows and trade missions, said, “It’s clear that Utah is a major player.” Shoutout to EVŌQbio, Matia Mobility, NanoSpot.ai, SINTX […]

Read More

Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit

Posted on by admin

SALT LAKE CITY–(BUSINESS WIRE)–Halia Therapeutics, a clinical stage biopharmaceutical company advancing innovative medicines to treat diseases driven by chronic inflammation, was invited to present today at the 4th Inflammasome Therapeutics Summit. Dr. David J. Bearss, CEO of Halia Therapeutics, will chair a panel entitled, “Advances in Proof-of-Concept Trials & Moving Towards the Clinic,” and also […]

Read More

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023

Posted on by admin

LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2022. Recent […]

Read More

Ortho Development Launches Enabling Technology for Total Knee

Posted on by admin

by Julie A. Vetalice Ortho Development BKS Total PSI has been released for commercial distribution in the United States in collaboration with Materialise, a provider of additive manufacturing software and 3D printing solutions. BKS Total PSI is compatible with Ortho Development’s BKS and BKS TriMax total knee replacement systems. BKS Total PSI, powered by Materialise, […]

Read More

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

Posted on by admin

SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care. UroSuite includes Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, […]

Read More